HSBC Holdings plc Reaffirms Reduce Rating for Hikma Pharmaceuticals Plc (HIK)
Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “reduce” rating reissued by investment analysts at HSBC Holdings plc in a report issued on Tuesday, StockTargetPrices.com reports. They presently have a GBX 1,800 ($23.32) target price on the stock. HSBC Holdings plc’s price target points to a potential upside of 25.26% from the stock’s previous close.
A number of other equities research analysts have also recently weighed in on the company. J P Morgan Chase & Co dropped their price target on Hikma Pharmaceuticals Plc from GBX 2,400 ($31.09) to GBX 1,800 ($23.32) and set a “neutral” rating on the stock in a research note on Friday, May 12th. Numis Securities Ltd restated a “buy” rating and issued a GBX 2,350 ($30.44) price target on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, May 11th. Jefferies Group LLC cut Hikma Pharmaceuticals Plc to an “underperform” rating and dropped their price target for the company from GBX 2,162 ($28.01) to GBX 1,450 ($18.78) in a research note on Wednesday, May 17th. Finally, Stifel Nicolaus restated a “buy” rating and issued a GBX 2,550 ($33.03) price target on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday, April 4th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of GBX 1,996.10 ($25.86).
Shares of Hikma Pharmaceuticals Plc (LON HIK) traded up 0.56% during trading on Tuesday, reaching GBX 1437.00. 394,327 shares of the company were exchanged. The stock’s market capitalization is GBX 3.46 billion. Hikma Pharmaceuticals Plc has a one year low of GBX 1,425.00 and a one year high of GBX 2,703.00. The company has a 50 day moving average price of GBX 1,651.86 and a 200-day moving average price of GBX 1,875.19.
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.